Form 4: Belite Bio CSO Executes Planned ADS Sale

Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of Belite Bio, Inc. via a 10b5-1 trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., sold a total of 1,000 American depositary shares (ADS) on April 24, 2026.
• The transactions were executed at weighted average prices ranging from $157.86 to $162.53 per share.
• Following these transactions, the reporting person retains beneficial ownership of 8,666 ADS.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-established 10b5-1 plan, which is a standard mechanism for executive financial planning.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, which typically indicates the transaction is not based on material non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in future short-term price appreciation, though this was a planned divestment.

Risks

• The reporting person's remaining stake in the company has decreased, which may marginally reduce alignment with shareholders if the position continues to be liquidated.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice in the biotechnology sector for liquidity and diversification purposes and generally does not signal a change in corporate strategy.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice for executives in the pharmaceutical and biotech industries to avoid allegations of insider trading.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the reporting person's holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Belite Bio, BLTE, Insider Trading, Form 4, Biotech, Nathan Mata